Stockreport

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]

NeuroSense Therapeutics Ltd. - Ordinary Shares  (NRSN) 
PDF Statistically significant survival benefit demonstrated, including 65% reduction in risk of death and 14-month median survival advantage Results published in JAMA Neu [Read more]